Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors

Circulation

Volumn 103, Issue 3, 2001, Pages 346-347

  Haffner, Steven M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

C reactive protein; Diabetes; Editorials; Statins

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

CYTOKINE PRODUCTION; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0035936519     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.3.346     Document Type: Review

References (21)

1. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
2. Impact of diabetes on mortality after the first myocardial infarction
3. The Diabetes Prevention Program: Design and methods for clinical trial in the prevention of type 2 diabetes
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
6. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
7. Effect of angiotensin-converting-enzyme inhibition compared with convention therapy on cardiovascular morbidity and mortality: The Captopril Prevention Project (CAPPP) randomized trial
8. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
9. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects
10. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Athcrosclerosis Risk in Communities Study
11. Effects of pravastatin, a 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension
12. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in non-diabetic subjects with mild hypertriglyceridemia
13. C-reactive proteins and other markers of inflammation in the prediction of cardiovascular disease in women
14. Long-term effects of pravastatin on plasma concentrations of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators
15. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH)
16. Chronic subclinical inflammation as part of the insulin resistance syndrome
17. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
18. Increased adipose tissue expression of turnout necrosis factor-α in human obesity and insulin resistance
19. Human subcutaneous adipose tissue secretes interleukin-a6 but not tumour necrosis factor-α in vivo
20. Regulation of the acute phase response by cytokines
21. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes